Genomic Health Upgraded By Canaccord, $44 Per Share Target Predicted

Loading...
Loading...
Shares of
Genomic Health, Inc.GHDX
were trading higher by more than 2.50 percent on Wednesday following a nod of confidence by Mark Massaro of Canaccord Genuity. Massaro upgraded shares of Genomic Health to Buy from Hold with a price target raised to $44 from a previous $26 following a proprietary survey and interviews with urologists. Massaro stated that he was surprised to discover from his survey that more doctors responded they are aware of Genomic Health's tests over
Myriad Genetics, Inc.MYGN
. The analyst noted this is a "testament" to the company's "solid" marketing and commercial initiatives. Massaro continued that 56 percent of doctors he surveyed indicated they are likely or highly likely to order Genomic Health's prostate test in 2016, versus only 48 percent for Myriad Generics' test. Massaro also noted that Genomic Health generated its strongest volume growth in two years during the recent third quarter with a 17 percent year over year total volume growth. The analyst stated that the company is looking to improve on its recent "strong" traction and can achieve "strong growth" even with other competing and "worthy" tests on the market. Finally, Massaro argued that the risk to reward profile on Genomic Health's stock has "swung to the upside," especially when factoring in a recent Medicare reimbursement decision for its prostate test in October. Bottom line, despite a recent "big" run of 50 percent in the stock following Genomic Health's third quarter print, the stock is still undervalued at 3.4x and 3.1x 2016 and 2017 revenue.
Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsGenomic HealthMark MassaroProstateProstate Tests
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...